Recently, FOSUN PHARMA (02196) successfully issued China's first private pharmaceutical industry medium-to-long-term technology innovation bond. China Merchants Bank served as the lead underwriter and bookrunner, while Bank of Beijing and Shanghai Pudong Development Bank acted as joint underwriters. The bond has a scale of 1 billion yuan, a 2-year term, and a coupon rate of 2.70%.
This technology innovation bond received enthusiastic subscription from various types of financial institutions including bank wealth management products, insurance companies, foreign banks, public mutual funds, and securities firms' proprietary trading. Meanwhile, China Bond Credit Enhancement Investment Co., Ltd. also actively participated in the bond subscription, representing regulatory support for this technology innovation bond issuance. The proceeds from this bond will provide strong financial support for FOSUN PHARMA's strategic layout in key technology innovation areas, accelerate the transformation and implementation of innovation achievements, and further consolidate and enhance the company's innovation competitiveness in the global pharmaceutical and healthcare industry.
Private economy is an important component of the socialist market economy and a vital force in advancing Chinese-style modernization. The private enterprise symposium held in February this year made comprehensive arrangements for promoting the healthy and high-quality development of private economy in the current and future periods, fully demonstrating the Party Central Committee's firm determination to support the development and growth of private economy. Subsequently, the People's Bank of China and four other departments jointly held a symposium on financial support for high-quality development of private enterprises, emphasizing coordinated efforts to resolve financing difficulties for private enterprises. In March this year, the National Association of Financial Market Institutional Investors released the "Action Plan for Further Supporting High-Quality Development of Private Enterprises in the Inter-bank Bond Market." These measures further optimized the bond financing environment for private enterprises.
On May 7, 2025, the People's Bank of China and China Securities Regulatory Commission jointly issued an announcement on supporting the issuance of technology innovation bonds. On the same day, the National Association of Financial Market Institutional Investors released the "Notice on Launching Technology Innovation Bonds and Building a 'Technology Board' in the Bond Market," proposing multiple supporting mechanisms for technology innovation bonds to guide bond funds to flow more efficiently, conveniently, and at lower cost to technology innovation fields, enhancing the bond market's capability to serve technology innovation.
Against this backdrop, FOSUN PHARMA combined its innovation-driven development strategy to guide low-cost bond market funds toward the frontier of biomedical technology, responding to central policy calls while significantly reducing the company's financing costs and optimizing debt structure. The successful issuance of this technology innovation bond further consolidates FOSUN PHARMA's leading position among domestic innovative pharmaceutical companies while providing strong support for the company's high-quality development.
Over more than 30 years since its establishment, FOSUN PHARMA has consistently taken innovation as its core development driving force. In the innovative drug field, since 2019, FOSUN PHARMA has cumulatively obtained approvals for 12 self-developed and licensed innovative drugs and biosimilar drugs, while successfully securing commercial rights for 8 innovative drugs in mainland China, covering core therapeutic areas including solid tumors, hematologic malignancies, and immune inflammation.
From January to May 2025, FOSUN PHARMA has had 4 products with 5 indications approved in China, the EU, and other regions, including the approval and launch of its first self-developed small molecule innovative drug Fumining® (Luvometinib Tablets), filling a gap in rare tumor treatment. The anti-PD-1 monoclonal antibody Serplulimab injection became the first PD-1 monoclonal antibody approved in the EU for extensive-stage small cell lung cancer (ES-SCLC) treatment, marking important progress in international expansion.
In the future, FOSUN PHARMA will continue to deepen innovation and transformation, committed to providing higher quality and more accessible products and services to patients and customers, creating sustainable value returns for shareholders.